epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-118, Phase II. In start-up

Treatment-resistant major depressive disorder

FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.

Twenty questions about the protocol, each tied to the research, and what every answer does to recruitment. The answers start as this study's template; change any of them to see what moves.

Fabrikam Neuroscience (fictional), Phase II, CNS and psychiatry. Protocol final May 2026. The answers start as this study's protocol; change any of them to see what moves.

All answers match the protocol.

Population and eligibility

How many non-essential exclusions does the protocol carry?

Organ-function limits, brain metastases, prior or concurrent cancers, performance status, and similar criteria that are not needed for safety.

  • Rate ×0.55: Protocol and population: Highly restrictive eligibility (D13)

Risks: PD-01PD-02EB-01EB-04PB-02

Which line of therapy does the study enrol?
  • No effect on the forecast
Is the population an orphan subgroup?

Not used with the rare-disease therapeutic area, which already carries the effect.

  • No effect on the forecast
Does entry require a biomarker, and how common is it?
  • No effect on the forecast
Does the protocol exclude common comorbidities?
  • Risk flag Any comorbidity cut participation odds to 0.76, and 81% of high-impact trials exclude common conditions; no per-site multiplier has been decided

Risks: PD-15PB-02

Is there an upper age limit?
  • Risk flag Older adults are under-enrolled: 25% of trial entrants against 63% of cancer patients

Risks: PB-10

Design

What does the control arm receive?
  • Rate ×0.75: Placebo or no added treatment (D15)

Risks: PD-05PD-17

Is the study blinded?
  • Rate ×0.8: Blinded (D15)

Risks: PD-06EB-03

What is the randomisation ratio?
  • No effect on the forecast
Is there a run-in or a washout longer than four weeks?
  • Screening Some patients are lost before randomisation; the size is not sourced

Risks: PD-09PD-10

Patient burden

How heavy is the visit and procedure schedule?

Compare with similar studies in the same area: number of visits, invasive procedures, questionnaires, overnight stays.

  • Rate ×0.8: Heavier than typical (D17)
  • Retention Higher burden raises drop-out

Risks: PD-03S-24EB-17

Are any visits done remotely or at home?
  • Risk flag Helps distant patients; no recruitment effect is established

Risks: PD-20

Did patients help design the protocol?
  • No effect on the forecast

Risks: PD-18EB-23

Operations

How settled is the protocol?
  • No effect on the forecast

Risks: PD-04PD-21S-14EB-18

How many vendors and systems will sites use?
  • Risk flag 22% of sites name the number of technologies and vendors as the biggest driver of complexity

Risks: S-18

What kind of sites will the study mostly use?
  • No effect on the forecast

Risks: S-06S-07

Have most sites worked with the sponsor before?
  • Rate ×0.75: Track record: New site, no history, through the expected mix of new and repeat sites

Risks: S-05PM-02

Environment

How many competing trials recruit the same patients?
  • Rate ×0.75: Competing trials: Heavy competition

Risks: S-21EB-02SH-30

Could the standard of care change during the study?
  • No effect on the forecast
Does the study depend on a comparator or backbone drug that has been in short supply?
  • No effect on the forecast

Build a site

A site's rate is built one factor at a time. The questionnaire sets each row, or pick an option to try a different kind of site in every country.

Each country's usual mix of site types, shifted by the site mix answer
Expected mix for mostly new sites
Highly restrictive eligibility ×0.55
Heavy competition ×0.75

Poland recruits fastest per site, at 0.130 a month

Patients randomised per site per month after each factor, by countryDots: filled is evidence-anchored, half-filled takes its direction from evidence, hollow is an assumption, hatched combines several; United States highlighted

Source: epiClinical evidence library; each factor's basis and source are in the rows beside the chart.

Shaded: Industry Phase III median, 0.4. Median 0.4 patients per site per month (interquartile range 0.2 to 0.6) in completed industry Phase III trials, 2016 to 2019 (PLOS ONE 2022; D01).

Shaded: UK public trials median, 0.92 to 0.95. Median 0.92 to 0.95 patients per centre per month in UK publicly funded trials (Walters 2017; Jacques 2022; D01).

Show data
Patients randomised per site per month after each factor, by country
FactorUnited StatesUnited KingdomSpainPoland
Therapeutic area0.4500.4500.4500.450
Country0.3380.3830.4500.630
Site type0.3410.3780.4410.663
Track record0.2950.3270.3810.573
Protocol and population0.1620.1800.2100.315
Patient acceptability0.0890.0990.1150.173
Competing trials0.0670.0740.0870.130

What this design does to the sites needed

To finish by May 2029 with 85% confidence, this design needs about 142 sites, the same as the protocol as written.

CountryPer site per month, protocol as writtenWith this designChangeSites needed, protocolWith this design
United States0.0670.067–00
United Kingdom0.0740.074–3030
Spain0.0870.087–7171
Poland0.1300.130–4141

Forecast this design

Risks these answers switch on

Open a risk to see its effect, what helped, what did not and the sources. Grade A is the strongest evidence and D the weakest.

Protocol and design

PD-01Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) Grade A
Effect
Negative; eligible pool ×0.48 to 0.53 against broadened criteria, with the hazard ratio unchanged or better.
What helped
ASCO-Friends modernised criteria and the FDA 2020 to 2026 guidances; data-driven criteria; adoption of 54 to 93% by criterion in NCI CTEP protocols.
What did not
Laboratory and washout exclusions carried forward unchanged across phases and years.
Sources
Harvey 2021; Liu 2021; Kim 2017 and 20212; Unger 2019
PD-02Number of eligibility criteria and complexity growth Grade B
Effect
Negative; more criteria independently associated with poor accrual (p = 0.013); complex trials randomise 59% of screened against about 75%.
What helped
Upstream protocol feasibility review and benchmarking against Tufts norms.
What did not
not found
Sources
Carlisle 2015; Getz 2014; Getz 2023
EB-01Overestimated eligible pool (Lasagna's law) Grade B
Effect
Negative; the commonest cause of recruitment-related discontinuation, first-quarter recruitment slower than planned in 63% of UK trials, and realistic yield quoted second-hand as one-tenth to one-third of the estimate.
What helped
Internal pilot with an explicit projection equation and stop-go review (Bertram 2019, descriptive); pre-trial accrual assessment (Schroen 2010: 67% against 47% sufficient accrual); evidence-based feasibility (CTTI 2018, no numbers).
What did not
A formal pilot phase as such (McDonald 2006: OR 1.09, no association); time extensions alone (Sully 2013: 55% against 54% reached target).
Sources
Briel 2016; McDonald 2006; van der Wouden 2007; Lasagna 1979; Feinstein 2001 via Bogin 2022
EB-04Restrictive eligibility criteria and protocol complexity Grade B
Effect
Negative; more eligibility criteria associated with accrual failure (p=0.013), 21.5% of cancer patients ineligible for an available trial, procedure counts rising 6.5 to 10.5% a year, and tissue sample required OR 1.26 with a CI including 1.
What helped
CTTI framework recommends limiting complexity and realistic eligibility (not quantified).
What did not
not found
Sources
Carlisle 2015; Unger 2019; Getz 2008; Getz 2018; Bennette 2016
PB-02Eligibility criteria exclude patients (comorbidity, age, performance status, language) Grade A
Effect
21.5% (10.9 to 34.6) of patients with an open trial are ineligible; any comorbidity cuts participation odds to 0.76; 81.3% of high-impact RCTs exclude common conditions; 19% of US trials require English.
What helped
Broadening criteria: dropping the comorbidity restrictions ASCO recommends removing could add up to 6,317 registrations a year; translation widens the pool.
What did not
not found
Sources
Unger 2019 JNCI; Unger 2019 JAMA Oncol; Van Spall 2007; Muthukumar 2021
PD-15Comorbidity exclusions Grade B
Effect
Negative; 65.6% of cancer patients have at least one comorbidity; participation OR 0.76.
What helped
Remove ASCO-flagged comorbidity restrictions, simulated to add up to 6,317 US registrations a year.
What did not
not found
Sources
Unger 2019 JAMA Oncology
PB-10Older adults under-enrolled Grade A
Effect
People aged 65 and over were 25% of trial entrants against 63% of cancer patients; trial median age 6.49 years below the population; 70 and over are 24% of FDA-registered trial participants against 42% of the cancer population.
What helped
Coverage policy raised 65 and over accrual (Unger 2006); broader eligibility and fewer performance-status cut-offs narrow the gap (Ludmir 2019).
What did not
Physician geriatric education, cluster RCT across 126 institutions, no effect (Kimmick 2005).
Sources
Hutchins 1999; Ludmir 2019; Sedrak 2021; FDA Snapshots 2024
PD-05Placebo or no-added-treatment control arm Grade B
Effect
Negative; willingness 30% against 39%; acceptance 60.5% against 80.6%.
What helped
All-active arms; add-on designs; equipoise-focused recruiter training through the QRI.
What did not
not found
Sources
Welton 1999; Jenkins 2000; Mills 2006; Uzzan 2023
PD-17Active comparator (against placebo) in registry data Grade B
Effect
Negative association only; poor accrual 23% against 16%.
What helped
not found
What did not
not found
Sources
Carlisle 2015
PD-06Blinded placebo-controlled against open design Grade A
Effect
Negative for blinding; an open design adds 10 percentage points (95% CI 7 to 13), high certainty.
What helped
Open or PROBE design where scientifically acceptable.
What did not
User-tested information leaflets added 1 point, no effect.
Sources
Treweek 2018
EB-03Blinded placebo-controlled design instead of open-label Grade A
Effect
Open design recruits 10 percentage points more of eligible patients (95% CI 7 to 13); at trial level active-comparator trials failed accrual more often than placebo trials (23% against 16%), and per-centre rates did not differ significantly.
What helped
Open-label or pragmatic design where scientifically acceptable (high certainty).
What did not
not found
Sources
Treweek 2018; Carlisle 2015; Walters 2017; Jacques 2022
PD-09Washout periods and concomitant-medication exclusions Grade C
Effect
Negative and qualitative; IBD patients deterred; criteria often arbitrary.
What helped
Remove arbitrary washouts, as the FDA final guidance of July 2026 requires.
What did not
not found
Sources
Harvey 2021 washout group; Liu 2021; Uzzan 2023
PD-10Run-in period before randomisation Grade C
Effect
Negative for randomised yield; narrows the population and overstates benefit.
What helped
Use only where there is a scientific need.
What did not
not found
Sources
Pablos-Méndez 1998
PD-03Procedural and visit burden (visits, blood draws, questionnaires) Grade B
Effect
Negative; burden score predicts screen failure, trial duration, and amendments (p < 0.01); oncology plans 29 visits against 16.
What helped
Score burden at design; prune non-core procedures, which are 22 to 25% of all procedures.
What did not
Sites rate decentralised trials as more burdensome for patient-facing procedures.
Sources
Smith 2021; Dirks 2025; Getz 2023
S-24Protocol complexity and site burden Grade B
Effect
Negative: procedures up 40.6%, sites per protocol up 60.1%, and enrolment duration up 36.9% (2010 to 2020); 70% of site staff say trials are much harder; about one-third of data collected is non-core.
What helped
Remove non-core data and procedures. Take site input on design.
What did not
not found
Sources
Clinical Trial Vanguard 2024; WCG 2024; Tufts CSDD 2022; PharmaVoice 2025
EB-17Follow-up burden and duration Grade C
Effect
Negative; trials with final follow-up beyond 18 months recruit at 0.71 per centre per month against 1.29 for follow-up within a month (p=0.054); time commitment is a key deterrent in the qualitative synthesis.
What helped
Reducing visit burden (CTTI, not quantified).
What did not
not found
Sources
Jacques 2022; Houghton 2020
PD-20Decentralised elements Grade C
Effect
Unclear; modelled value only; sites split on whether they add or remove burden.
What helped
Hybrid elements for follow-up visits.
What did not
A fully remote trial under-recruited despite a very large outreach funnel.
Sources
FDA 2024; DiMasi 2023; Nassif 2023; Florez 2024
PD-04Substantial protocol amendments Grade B
Effect
Negative; 76% of protocols amended, 3.3 each, 260 days to implement, 215 days of version mismatch, enrolment against plan reduced; $141,000 to $535,000 each.
What helped
Governance review before approval, since about 40% of amendments occur before first patient first dose.
What did not
Amendments raise screening volume but not enrolment against plan.
Sources
Getz 2016; Getz 2024; Botto 2024; Getz 2014
S-14Protocol amendments before and after activation Grade B
Effect
Negative on time: 24% of studies amended before activation, a 4 to 6 week delay typical and 10 weeks or more for about 20% of centres, 260 days to implement an amendment, and 82% of Phase III protocols amended.
What helped
Finalise the protocol before feasibility. Take site input on design (46% of sites ask for it).
What did not
not found
Sources
Clinical Trial Vanguard 2024; AACI 2026

Site

S-06Site type: activation speed Grade A
Effect
Negative for academic and hospital sites: median 8.1 months versus 4.4 months for independent sites; 9% versus 54% start within 60 days; 21%, 34%, and 80% within 60 days for AMCs, hospital systems, and investigative sites.
What helped
Standardised start-up workflow with a site navigator (133 versus 277 days). Master contracts. UK National Contract Value Review (305 to 194 days).
What did not
Sequential review layers. Pre-activation amendments, which add 4 to 6 weeks each.
Sources
Smith (WCG) 2024; Advarra 2020; WCG 2025; Dilts and Sandler 2006
S-07Site type: enrolment rate Grade C
Effect
Positive for research-focused sites: 41% better enrollers than practice-focused sites (72 protocols); in-network investigators about 25% more; network sites may have an advantage on a small sample.
What helped
Select sites with dedicated research infrastructure and a recruitment plan.
What did not
not found
Sources
Getz 2011; Dirks, Chambers, and Getz 2026; Yang 2018
S-05New-to-sponsor site Grade B
Effect
Negative on time: 28 to 30% of sites are new to the sponsor and initiation takes about 10 weeks longer; sites with 6 to 10 trials' experience are more likely to hit target; no measured rate penalty.
What helped
Repeat-site preference where the patient pool allows. Master agreements and central IRB.
What did not
not found
Sources
Getz 2011; WCG 2018; Getz 2016; Miseta 2017
PM-02Academic and hospital sites, and sites new to the sponsor, take longer to activate Grade B
Effect
Delays activation by months: 8.1 to 9.4 months for academic medical centres against 4.4 to 4.8 for independent sites, 12.9 against 7.9 months from pre-study visit to first patient, and 35.6 weeks for new sites against 25.7 for repeat sites.
What helped
not found
What did not
not found
Sources
WCG Data Intelligence 2023 to 2025; Tufts CSDD 2012; Tufts CSDD 2018
S-21Competing trials Grade B
Effect
Negative when the eligible pool is scarce: OR 1.88 (1.32 to 2.68) for low accrual per competing trial per 10,000 eligible patients per year; no effect when the pool is large; 3,042 immuno-oncology trials sought 577,076 patients.
What helped
Redirect referrals to non-overlapping sites and re-engage the PI (anecdotal). Choose indications and regions with slack.
What did not
Adding sites into the same saturated pool.
Sources
Bennette 2016; Hutchinson 2022; Tang 2018; ClinOops 2026
EB-02Competing trials for the same patients Grade A
Effect
Negative; OR 1.88 (95% CI 1.32 to 2.68) for low accrual per additional competing trial per 10,000 eligible patients per year, with low-accrual trials facing a median 4.4 against 2.9 competing trials.
What helped
Not tested as an intervention; Bennette's model identified a top-decile risk group with 52% low accrual, usable for site and country selection.
What did not
not found
Sources
Bennette 2016; Schroen 2011
SH-30Competing trials at a site Grade D
Effect
Not found; practitioner belief that concurrent trials dilute per-trial enrolment is widespread but anecdotal.
What helped
not found
What did not
not found
Sources
not found (practitioner belief, anecdotal)

Sponsor, CRO and model

PD-18No patient and public involvement in design Grade A
Effect
Positive when present; enrolment OR 1.16 (1.01 to 1.34); lived-experience involvement OR 3.14, exploratory.
What helped
Patient and public involvement in protocol design.
What did not
Retention was not improved (OR 1.16, 0.33 to 4.14).
Sources
Crocker 2018
EB-23Patient and public involvement in design Grade B
Effect
Positive; PPI interventions associated with higher enrolment (OR 1.16, 1.01 to 1.34), larger with lived-experience involvement (OR 3.14 against 1.07, exploratory); PRioRiTy question 3 asks exactly this.
What helped
Involving people with lived experience of the condition in planning.
What did not
Retention effect inconclusive (OR 1.16, 0.33 to 4.14).
Sources
Crocker 2018; Healy 2018
PD-21No upstream protocol feasibility review Grade B
Effect
Negative; 23 to 45% of amendments avoidable and about 40% occur before first patient first dose.
What helped
Cross-functional governance review; the CTTI three-area framework; critical-to-quality factors at planning.
What did not
not found
Sources
Getz 2014, 2016, and 202423; Huang 2018; ICH E8(R1)
EB-18Protocol amendments Grade B
Effect
Negative; 57% of protocols had at least one substantial amendment, 45% avoidable; amended protocols recruited longer and enrolled fewer than planned; median direct cost $535,000 in Phase III; over 40% amend before first patient visit, delaying about four months (secondary).
What helped
Protocol governance and simplification (not quantified).
What did not
not found
Sources
Getz 2016; Getz 2011 via Fogel 2018
S-18Technology burden Grade B
Effect
Negative on site time, unquantified for enrolment: 60% of sites use 20 or more systems daily, about 10 to 12 applications per site in 2015, 46% say too many separate technologies and 74% cite login tracking (2020), 40% of sites spend 5 to 15 hours per month per study on unpaid training, and 19% rank sponsor technology a top challenge.
What helped
Accept site-preferred systems. Consistent technology across a sponsor's studies. Paid training.
What did not
not found
Sources
WCG 2024; SCRS 2023 Site Landscape; Bechtel 2024; Florence 2024; SCRS 2020